Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

INTRODUCTION: Sonidegib is approved to treat locally advanced basal cell carcinoma (laBCC) in the USA, EU, Switzerland, and Australia and metastatic basal cell carcinoma (mBCC) in Switzerland and Australia in patients not amenable to surgery or radiotherapy. Vismodegib is approved to treat patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutzmer, Ralf, Loquai, Carmen, Robert, Caroline, Dréno, Brigitte, Guminski, Alexander, Lewis, Karl, Arntz, Ramon, Martelli, Serena, Squittieri, Nicholas, Kheterpal, Meenal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484385/
https://www.ncbi.nlm.nih.gov/pubmed/34490549
http://dx.doi.org/10.1007/s13555-021-00588-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484385/
https://www.ncbi.nlm.nih.gov/pubmed/34490549
http://dx.doi.org/10.1007/s13555-021-00588-8

Ejemplares similares